| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Serum fibroblast growth factor-23 levels predict the future refractory hyperparathyroidism in dialysis patients.
|
Kidney Int
|
2005
|
2.26
|
|
2
|
Clinical practice guideline for the management of chronic kidney disease-mineral and bone disorder.
|
Ther Apher Dial
|
2013
|
2.07
|
|
3
|
Renal disease in the elderly and the very elderly Japanese: analysis of the Japan Renal Biopsy Registry (J-RBR).
|
Clin Exp Nephrol
|
2012
|
1.95
|
|
4
|
Sevelamer hydrochloride and calcium bicarbonate reduce serum fibroblast growth factor 23 levels in dialysis patients.
|
Ther Apher Dial
|
2005
|
1.78
|
|
5
|
Overview of regular dialysis treatment in Japan (as of 31 December 2008).
|
Ther Apher Dial
|
2010
|
1.62
|
|
6
|
Most patients with coronary artery calcification have no coronary artery stenosis and hyperphosphatemia should be important in reevaluating the K/DOQI guidelines.
|
Ther Apher Dial
|
2006
|
1.39
|
|
7
|
An overview of regular dialysis treatment in Japan (as of 31 December 2010).
|
Ther Apher Dial
|
2012
|
1.37
|
|
8
|
Overview of regular dialysis treatment in Japan (as of 31 December 2011).
|
Ther Apher Dial
|
2013
|
1.29
|
|
9
|
Serum phosphate and calcium should be primarily and consistently controlled in prevalent hemodialysis patients.
|
Ther Apher Dial
|
2013
|
1.14
|
|
10
|
Overview of regular dialysis treatment in Japan as of 31 December 2006.
|
Ther Apher Dial
|
2008
|
1.14
|
|
11
|
Regulation of fibroblast growth factor 23 production in bone in uremic rats.
|
Nephron Physiol
|
2009
|
1.11
|
|
12
|
Overview of regular dialysis treatment in Japan (as of 31 December 2009).
|
Ther Apher Dial
|
2012
|
1.11
|
|
13
|
An overview of regular dialysis treatment in Japan (as of 31 December 2012).
|
Ther Apher Dial
|
2014
|
1.11
|
|
14
|
Fibroblast growth factor 23 production in bone is directly regulated by 1{alpha},25-dihydroxyvitamin D, but not PTH.
|
Am J Physiol Renal Physiol
|
2010
|
1.08
|
|
15
|
Management of patients with advanced secondary hyperparathyroidism: the Japanese approach.
|
Nephrol Dial Transplant
|
2002
|
1.02
|
|
16
|
Mild renal dysfunction is a risk factor for a decrease in bone mineral density and vertebral fractures in Japanese postmenopausal women.
|
J Clin Endocrinol Metab
|
2010
|
1.01
|
|
17
|
Fibroblast growth factor (FGF)-23 in patients with primary hyperparathyroidism.
|
Eur J Endocrinol
|
2004
|
1.01
|
|
18
|
Tolvaptan, a selective oral vasopressin V2 receptor antagonist, ameliorates podocyte injury in puromycin aminonucleoside nephrotic rats.
|
Clin Exp Nephrol
|
2009
|
1.01
|
|
19
|
An overview of regular dialysis treatment in Japan (as of 31 December 2007).
|
Ther Apher Dial
|
2009
|
0.98
|
|
20
|
Increased circulating levels of osteoclastogenesis inhibitory factor (osteoprotegerin) in patients with chronic renal failure.
|
Am J Kidney Dis
|
2002
|
0.90
|
|
21
|
Mechanism of phosphate-induced calcification in rat aortic tissue culture: possible involvement of Pit-1 and apoptosis.
|
Clin Exp Nephrol
|
2009
|
0.89
|
|
22
|
Overview of regular dialysis treatment in Japan (as of 31 December 2005).
|
Ther Apher Dial
|
2007
|
0.88
|
|
23
|
Current therapeutic strategies for acute kidney injury.
|
Clin Exp Nephrol
|
2012
|
0.86
|
|
24
|
Comparison between whole and intact parathyroid hormone assays.
|
Ther Apher Dial
|
2011
|
0.85
|
|
25
|
Efficacy of combined sevelamer and calcium carbonate therapy for hyperphosphatemia in Japanese hemodialysis patients.
|
Ther Apher Dial
|
2005
|
0.84
|
|
26
|
IRMA (whole PTH) is a more useful assay for the effect of PTH on bone than the Allegro intact PTH assay in CAPD patients with low bone turnover marker.
|
Nephrol Dial Transplant
|
2003
|
0.84
|
|
27
|
Inhibitory effects of etidronate on the progression of vascular calcification in hemodialysis patients.
|
Ther Apher Dial
|
2004
|
0.83
|
|
28
|
Effects of Cyclophosphamide Pulse Therapy on the Clinical and Histopathological Findings, Particularly Crescent Formation, in a Patient with Adult-onset Steroid-refractory Henoch-Schönlein Purpura Nephritis.
|
Intern Med
|
2015
|
0.82
|
|
29
|
Role of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism.
|
Ther Apher Dial
|
2005
|
0.82
|
|
30
|
Fibroblast growth factor-23 in patients with Graves' disease before and after antithyroid therapy: its important role in serum phosphate regulation.
|
J Clin Endocrinol Metab
|
2005
|
0.82
|
|
31
|
Diabetes mellitus suppresses hemodialysis-induced increases in tear fluid secretion.
|
BMC Res Notes
|
2014
|
0.82
|
|
32
|
The negative Ca(2+) balance is involved in the stimulation of PTH secretion.
|
Nephron
|
2002
|
0.82
|
|
33
|
A new classification of Diabetic Nephropathy 2014: a report from Joint Committee on Diabetic Nephropathy.
|
Clin Exp Nephrol
|
2015
|
0.81
|
|
34
|
Tonsillectomy with steroid pulse therapy has more effect on the relapse rate than steroid pulse monotherapy in IgA nephropathy patients.
|
Clin Nephrol
|
2013
|
0.81
|
|
35
|
Effect of erythropoietin-stimulating agent on uremic inflammation.
|
J Inflamm (Lond)
|
2012
|
0.81
|
|
36
|
Improved assessment of aortic calcification in Japanese patients undergoing maintenance hemodialysis.
|
Intern Med
|
2010
|
0.81
|
|
37
|
Fibroblast growth factor-23 (FGF23) in patients with transient hypoparathyroidism: its important role in serum phosphate regulation.
|
Endocr J
|
2007
|
0.80
|
|
38
|
Calcium oxalate crystal deposition in metabolic syndrome model rat kidneys.
|
Int J Urol
|
2010
|
0.80
|
|
39
|
Direct comparison between two 1-84PTH assays in dialysis patients.
|
Nephron Clin Pract
|
2005
|
0.80
|
|
40
|
Influence of renin-angiotensin system on serum parathyroid hormone levels in uremic patients.
|
Clin Exp Nephrol
|
2011
|
0.80
|
|
41
|
Highly concentrated calcitriol and its analogues induce apoptosis of parathyroid cells and regression of the hyperplastic gland--study in rats.
|
Nephrol Dial Transplant
|
2007
|
0.80
|
|
42
|
Prospective randomized multicenter trial of sevelamer hydrochloride and calcium carbonate for the treatment of hyperphosphatemia in hemodialysis patients in Japan.
|
Ther Apher Dial
|
2005
|
0.79
|
|
43
|
Circulating 1-84 PTH and large C-terminal PTH fragment levels in uremia.
|
Clin Exp Nephrol
|
2003
|
0.78
|
|
44
|
A new xanthine oxidase inhibitor: the uric acid reduction and additional efficacy in CKD patients.
|
Clin Exp Nephrol
|
2014
|
0.78
|
|
45
|
Direct injection of calcitriol or its analog improves abnormal gene expression in the hyperplastic parathyroid gland in uremia.
|
Am J Nephrol
|
2007
|
0.78
|
|
46
|
Nephrologist care for 12 months or more increases hemodialysis initiation with permanent vascular access.
|
Clin Exp Nephrol
|
2011
|
0.78
|
|
47
|
[The role of phosphatonin in phosphate metabolism].
|
Clin Calcium
|
2005
|
0.78
|
|
48
|
[Continuous renal replacement therapy in acute kidney injury].
|
Nihon Jinzo Gakkai Shi
|
2013
|
0.78
|
|
49
|
Mineral Composition of Phosphate-Induced Calcification in a Rat Aortic Tissue Culture Model.
|
J Atheroscler Thromb
|
2015
|
0.78
|
|
50
|
Randomized controlled open-label trial of vitamin E-bonded polysulfone dialyzer and erythropoiesis-stimulating agent response.
|
Clin J Am Soc Nephrol
|
2013
|
0.77
|
|
51
|
Efficacy and safety of lanthanum carbonate in pre-dialysis CKD patients with hyperphosphatemia: a randomized trial.
|
Clin Nephrol
|
2014
|
0.77
|
|
52
|
Clinical significance of the K/DOQI bone guidelines in Japan.
|
Am J Kidney Dis
|
2004
|
0.77
|
|
53
|
Vascular calcification estimated by aortic calcification area index is a significant predictive parameter of cardiovascular mortality in hemodialysis patients.
|
Clin Exp Nephrol
|
2011
|
0.77
|
|
54
|
Significance of serum magnesium as an independent correlative factor on the parathyroid hormone level in uremic patients.
|
J Clin Endocrinol Metab
|
2014
|
0.77
|
|
55
|
Binding of highly concentrated maxacalcitol to the nuclear vitamin D receptors of parathyroid cells.
|
Nephrol Dial Transplant
|
2007
|
0.77
|
|
56
|
Preventive Strategies for Vascular Calcification in Patients with Chronic Kidney Disease.
|
Contrib Nephrol
|
2016
|
0.76
|
|
57
|
Reduced expression of perlecan in the aorta of secondary hyperparathyroidism model rats with medial calcification.
|
Ren Fail
|
2010
|
0.76
|
|
58
|
Circulating osteoprotegerin is not removed through haemodialysis membrane.
|
Nephrol Dial Transplant
|
2002
|
0.75
|
|
59
|
A 12-week dose-escalating study of etelcalcetide (ONO-5163/AMG 416),
a novel intravenous calcimimetic, for secondary hyperparathyroidism in
Japanese hemodialysis patients
.
|
Clin Nephrol
|
2017
|
0.75
|
|
60
|
[Dialysis medicine and risk management in disaster].
|
Nihon Jinzo Gakkai Shi
|
2013
|
0.75
|
|
61
|
[Clinical aspect of recent progress in phosphate metabolism. Management of hyperphosphagtemia].
|
Clin Calcium
|
2009
|
0.75
|
|
62
|
[Arteriosclerosis and vascular calcification in chronic kidney disease (CKD) patients].
|
Clin Calcium
|
2007
|
0.75
|
|
63
|
[PTH assay: whole PTH assay (new IRMA assay)].
|
Clin Calcium
|
2003
|
0.75
|
|
64
|
Low blood osteoprotegerin levels are a predictor to poor prognosis in Japanese patients on hemodialysis due to diabetic nephropathy.
|
Ther Apher Dial
|
2008
|
0.75
|
|
65
|
Left ventricular hypertrophy was infrequent in patients starting dialysis after undergoing a strict blood pressure control in the pre-dialytic period.
|
Intern Med
|
2002
|
0.75
|
|
66
|
[Molecular targeting therapy in rheumatoid arthritis].
|
Nihon Jinzo Gakkai Shi
|
2012
|
0.75
|
|
67
|
[Therapeutic consideration in the intensive care unit of patients with chronic kidney disease or end-stage renal disease].
|
Nihon Jinzo Gakkai Shi
|
2015
|
0.75
|
|
68
|
Colestimide can be used as a phosphate binder to treat uraemia in end-stage renal disease patients.
|
Nephrol Dial Transplant
|
2003
|
0.75
|
|
69
|
[Suppressive effects of bisphosphonates on the vascular calcification in ESRD patients].
|
Clin Calcium
|
2002
|
0.75
|
|
70
|
[Action of parathyroid hormone on the kidney].
|
Nihon Rinsho
|
2005
|
0.75
|
|
71
|
[Conservative management and pharmacological intervention for CKD-related mineral and bone disorder].
|
Nihon Jinzo Gakkai Shi
|
2014
|
0.75
|
|
72
|
Calcium Overload Accelerates Phosphate-Induced Vascular Calcification Via Pit-1, but not the Calcium-Sensing Receptor.
|
J Atheroscler Thromb
|
2016
|
0.75
|
|
73
|
[Parathyroid and bone. Secondary hyperparathyroidism after renal transplantation].
|
Clin Calcium
|
2007
|
0.75
|
|
74
|
[Management of phosphate in chronic kidney disease--Clinical trials of lanthanum carbonate].
|
Clin Calcium
|
2009
|
0.75
|
|
75
|
[Newly development of phosphate binders in hyperphosphatemic patients with kidney dysfunction].
|
Clin Calcium
|
2012
|
0.75
|
|
76
|
[Classification of Diabetic Nephropathy 2014].
|
Nihon Jinzo Gakkai Shi
|
2014
|
0.75
|
|
77
|
[Bone disease in secondary hyperparathyroidism].
|
Nihon Rinsho
|
2004
|
0.75
|
|
78
|
Application of "homogeneous assay for fluorescence concentrated on membrane" to the analysis of the substrate specificity of protease.
|
Biosci Biotechnol Biochem
|
2010
|
0.75
|
|
79
|
[Molecular biology in regulation of kidney functions: PTH (parathyroid hormone)].
|
Nihon Rinsho
|
2006
|
0.75
|
|
80
|
[Molecular mechanism of vascular calcification in renal failure].
|
Clin Calcium
|
2002
|
0.75
|
|
81
|
Comparison of sevelamer hydrochloride with colestimide, administered alone or in combination with calcium carbonate, in patients on hemodialysis.
|
Ther Apher Dial
|
2008
|
0.75
|
|
82
|
[Renal osteodystrophy (ROD)].
|
Nihon Rinsho
|
2006
|
0.75
|
|
83
|
[Secondary osteoporosis UPDATE. Therapy for bone-mineral disease in CKD-5D patients].
|
Clin Calcium
|
2010
|
0.75
|
|
84
|
[Acute kidney injury: progress in diagnosis and treatments. Topics: V. Prevention and treatments; 3. Renal replacement therapy for acute kidney injury].
|
Nihon Naika Gakkai Zasshi
|
2014
|
0.75
|
|
85
|
[Basic and clinical aspects of calcimimetics. The clinical effect and usefulness of Cinacalcet as a calcimimetics on three CKD-5D patients undergoing hemodialysis with refractory secondary hyperparathyroidism].
|
Clin Calcium
|
2008
|
0.75
|
|
86
|
Surgical verification of percutaneous maxacalcitol injection therapy on enlarged parathyroid glands in chronic dialysis patients.
|
Nephrol Dial Transplant
|
2003
|
0.75
|
|
87
|
[Clinical investigation of the effect of blood sampling day on serum phosphorus concentration].
|
Clin Calcium
|
2005
|
0.75
|
|
88
|
Need for education on the differential diagnosis between chronic glomerulonephritis and nephrosclerosis, and treatment of both conditions to reduce the number of patients requiring hemodialysis in Wakayama.
|
Intern Med
|
2012
|
0.75
|
|
89
|
[Advances in blood purification medicine in 2008].
|
Nihon Jinzo Gakkai Shi
|
2009
|
0.75
|
|
90
|
[Fibroblast growth factor (FGF)-23 in patients with hypoparathyroidism].
|
Clin Calcium
|
2005
|
0.75
|
|
91
|
[significance of PTH (1-84) assay in the management of chronic renal failure and the current status and future of the treatment of renal osteopathy].
|
Clin Calcium
|
2005
|
0.75
|
|
92
|
[CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder). Lanthanum carbonate and new phosphate binders in patients with chronic kidney disease].
|
Clin Calcium
|
2010
|
0.75
|